Understand the source comparison
The Comparison: DSIP, Epithalon, and MK 677 in Sleep Research
| Peptide | Primary Mechanism | Sleep Phase Affected | Research Maturity | Typical Dosing Range (Research Models) | Reconstitution Stability | Bottom Line ||—|—|—|—|—|—|| DSIP | Delta-opioid receptor agonism | Slow-wave (NREM Stage 3) | Early-stage. Limited hu
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- | Peptide | Primary Mechanism | Sleep Phase Affected | Research Maturity | Typical Dosing Range (Research Models) | Reconstitution Stability | Bottom Line ||—|—|—|—|—|—|| DSIP | Delta-opioid receptor agonism | Slow-wave (NREM Stage 3) | Early-stage. Limited human trials | 5–10 nmol intracerebroventricular or 0.5–1 mg subcutaneous | 30 days at 2–8°C | Most direct slow-wave modulation, but delivery method limits practical use || Epithalon | Pineal gland melatonin upregulation | Circadian alignment, REM regulation | Preliminary. Narrow research base | 5–10 mg subcutaneous daily × 10–20 days | 28 days at 2–8°C | Cumulative effect requires sustained protocol. Single doses ineffective || MK 677 | Growth hormone secretagogue (GHSR-1a agonist) | REM and slow-wave amplification | Moderate. Phase II human data exists | 10–25 mg oral daily | Oral formulation. Stable at room temp | Most studied option; amplifies existing sleep phases rather than inducing sleep || Dihexa | HGF/c-Met pathway modulat
- DSIP shows the clearest direct effect on slow-wave sleep architecture, but the delivery challenge is significant: peripheral administration (subcutaneous or intramuscular) produces weak CNS penetration. Most early research used intracerebroventricular injection, which isn't practical outside controlled lab settings. Subcutaneous dosing at 0.5–1 mg has shown some benefit in small trials, but the response is inconsistent. Likely because blood-brain barrier permeability varies across subjects.
- Epithalon's mechanism is elegant: rather than forcing a sleep state, it restores the pineal gland's natural melatonin rhythm. The tradeoff is time: you won't see measurable sleep improvements after one or two doses. Research protocols typically run 10–20 days before circadian markers shift. That makes Epithalon unsuitable for acute sleep disruption. It's a rhythm-restoration tool, not an immediate intervention.
- MK 677 sits in a different category: it's not a sleep peptide per se, but a growth hormone secretagogue that happens to amplify the depth of natural sleep stages. The 1997 JCEM study remains the strongest evidence for its sleep-enhancing properties, showing that daily oral dosing increased both REM duration and slow-wave sleep in healthy adults. The side-effect profile is well-documented. Transient water retention, increased appetite, and mild insulin resistance at higher doses. Which gives researchers a clearer risk-benefit picture than DSIP or Epithalon provide.